Login to Your Account

Joining IPO queue, Viventia aims for $86M for bladder cancer trial

By Jennifer Boggs
Managing Editor

Thursday, October 22, 2015
Viventia Bio Inc., which recently launched a phase III study testing lead candidate Vicinium in bladder cancer, is looking to raise up to $86.25 million in an IPO and gain a listing on Nasdaq under the ticker VITA.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription